Cochrane News

Subscribe to Cochrane News feed
Updated: 1 hour 24 min ago

Cochrane’s Future Publishing and Open Access Arrangements

Thu, 04/26/2018 - 17:54

Today Cochrane announces important decisions on its future publishing and open access arrangements, part of its commitment of making Cochrane evidence freely and openly accessible to everyone all over the world.

Cochrane has agreed improved terms and a two-year extension of its existing publishing agreement with John Wiley & Sons, Limited, which means Wiley will continue to publish the Cochrane Library until 31st December 2020. In June 2018 the enhanced Cochrane Library will be launched on a new publishing platform (built by the specialist third party HighWire), allowing many new features to be developed and launched over the next two years that will offer increasing value for Cochrane Library subscribers.

Cochrane will also open and run a competitive tender process in 2019 to establish who will publish the Cochrane Library from 1st January 2021. Future publishers will be required to show how they plan to partner with Cochrane to develop the Library so that it becomes the ‘Home of Evidence’ at the heart of health decision making around the world; whilst also maintaining and expanding Cochrane Library revenues. Royalties from sales of the Cochrane Library are the major source of funds for the charity – over £6 million in 2017 – despite 3.66 billion people around the world having one-click access to the Library either through highly-subsidised national licences (for 1.5 billion) or free provision for populations in low- and middle-income countries eligible under the WHO’s HINARI initiative (2.1 billion).

This is part of Cochrane’s extensive commitment in its Strategy to 2020 that aims to put Cochrane evidence at the heart of health decision-making all over the world.

Since February 2013, when the current contract with Wiley was signed, Cochrane is proud to have:

  • Provided free access to new and updated Cochrane Reviews for all readers worldwide 12 months after publication, under our ‘green’ Open Access scheme. Over half of all Cochrane Reviews are now available this way.
  • Deposited all Cochrane Reviews in PubMed Central for open access publication 12 months after publication (started September 2016).
  • Made all Cochrane Review protocols freely available on publication (since February 2016).
  • Provided Cochrane author teams with the option to pay an Article Publication Charge in order to make their new and updated reviews freely available worldwide on publication, and to take up other benefits of a Creative Commons licence, via a ‘gold’ Open Access option.

Cochrane’s Governing Board has decided to continue these policies under the post-2020 publishing arrangements, but to postpone implementation of the target set out in Strategy to 2020 to make all Cochrane Reviews open access ‘immediately upon publication’. This remains Cochrane’s long-term ambition, but it will be implemented only when the Governing Board are confident that it will not undermine Cochrane’s future sustainability and, therefore, its ability to meet other strategic goals. 

Cochrane’s Governing Board Co-Chair, Martin Burton said: “Extending our already very successful partnership with Wiley until the end of Strategy to 2020 will give us the time to develop exciting new products and features in the Cochrane Library, focus on the transformative organizational changes we need to deliver in the next two years, provide us with a stable and more predictable financial base, whilst also allowing us adequate time to choose our future publishing partners.” Cochrane’s Chief Executive Officer, Mark Wilson added: “We’re enormously proud of the Open Access offering that we’ve established over the last five years, which will make an ever-larger proportion of Cochrane Reviews universally accessible in the future. We plan to review our Open Access policy regularly after 2020 with our publishing partners to ensure we balance Cochrane’s financial viability with our long-term goal of providing immediate free access to Cochrane Reviews for the whole world.”

For more information on access options to the Cochrane Library, please visit cochranelibrary.com.

Monday, April 30, 2018

Cochrane Classmate webinar - 17 May 2018

Mon, 04/23/2018 - 20:30

Looking for an innovative tool to teach evidence production? Cochrane Classmate might well be the answer!

Classmate is a trainers’ toolkit that allows you to create exciting, interactive tasks that help your students learn about evidence production. It is easy to use, and its first release is now available free of charge to anyone interested.

Register for our webinar to learn about Classmate and the benefits of using this new online learning environment. The webinar is on Thursday 17th May, 12.30-1.30pm BST.

Who is Classmate for? Anyone who teaches on topics related to evidence production, such as evidence-based medicine, systematic review production, understanding PICO, study designs, citation screening or research reporting standards. Classmate can be used in a variety of contexts such as university courses, workshops or other events.

What will be covered in the webinar? You’ll be taken on a tour of Classmate, including how to create a learning activity, invite students to the activity and monitor their progress. You’ll see the modules currently available on Classmate and hear about others launching soon.



Support for Project Transform was provided by Cochrane and the National Health and Medical Research Counc12/12/1996il of Australia (APP1114605). The contents of the published material are solely the responsibility of the Administering Institution, a Participating Institution or individual authors and do not reflect the views of the NHMRC.

Tuesday, April 24, 2018

Cochrane seeks Finance Officer (Purchase Ledger) - London, UK

Fri, 04/20/2018 - 20:45

Specifications: Part Time 30 hours per week
Salary: Competitive
Location: London
Application Closing Date: Friday 4th May 2018

This role is an exciting opportunity to use your experience as a Finance Officer to make a difference in the field of health care research. 

The Finance Officer will maintain the sales and purchase ledgers for Cochrane, Collaboration Trading and Cochrane Innovations, including processing expenses for CET members, facilitating payments and reconciling bank statements.

We are looking for a self-motivated and highly organised individual who is able to work effectively and collaboratively with a diverse range of contacts across the world.  The successful candidate will also have:

  • Demonstrable experience in all aspects of purchase ledger
  • Experience of using Xero
  • Intermediate Microsoft Excel skills
  • Excellent communication skills with the ability to build relationships across the business
  • Have the proven ability to work both independently and as part of a team
  • Ability to work to tight deadlines
  • Can demonstrate problem solving skills and a practical approach to dealing with day-to-day issues
  • Proven experience of building productive working relationships, both internally and externally
  • Ability to communicate clearly with non-finance employees about financial matters
  • Commitment to Cochrane’s mission and values

Cochrane is a global, independent network of health practitioners, researchers, patient advocates and others, responding to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesizing research findings to produce the best available evidence on what can work, what might harm and where more research is needed. Our work is recognised as the international gold standard for high quality, trusted information.

If you would like to apply for this position, please send a CV along with a supporting statement to recruitment@cochrane.org with “Finance Officer” in the subject line.  The supporting statement should indicate why you are applying for the post, and how far you meet the requirements for the post outlined in the job description using specific examples.  List your experience, achievements, knowledge, personal qualities, and skills which you feel are relevant to the post.

For further information, please download the full job description.
Deadline for applications:
Friday 4th May 2018(12 midnight GMT)
Interviews to be held on: Monday 14th May 2018

Monday, April 23, 2018 Category: Jobs

Featured Review: First-line drugs for hypertension

Fri, 04/20/2018 - 20:15

Thiazides best first choice for hypertension

High blood pressure or hypertension can increase the risk of heart attacks and stroke. One of the most important decisions in treating people with elevated blood pressure is what drug class to use first. This decision has important consequences in terms of health outcomes and cost.

The Cochrane Hypertension Group, which is part of Cochrane Circulation and Breathing, updated their original 2009 Cochrane Review looking at what drug class was the best first-line choice in treating adult patients with raised blood pressure. No new trials were found in the update; keeping the total at 24 studies, that randomly assigned 58,040 adult people (mean age 62 years) with high blood pressure, to four different drug classes or placebo. Duration of these studies ranged from three to five years. Drug classes studied included thiazide diuretics, beta-blockers, ACE inhibitors, and calcium channel blockers.

The Cochrane Review concluded that most of the evidence demonstrated that first-line low-dose thiazides reduced mortality, stroke, and heart attack. No other drug class improved health outcomes better than low-dose thiazides. Beta-blockers and high-dose thiazides were inferior. High-quality evidence supported that low-dose thiazides should be used first for most patients with elevated blood pressure. Fortunately, thiazides are also very inexpensive.

“The decision as to which drug to use first-line for the management of hypertension is an important one for clinicians" says James Wright the first author of this updated Cochrane Review.  “Knowing that the evidence for first-line thiazides is better than other classes of drugs is great news for clinicians as thiazides are also the least expensive and have other advantages.  Both clinicians and patients can be reassured that Cochrane evidence, recognized as the gold standard of health evidence, supports this.”

Monday, April 23, 2018

Cochrane marches for science

Fri, 04/20/2018 - 16:39

The March for Science is a celebration of passion for science and the many ways science serves our global communities.

Cochrane officially supports and is in partnership with the March for Science. The March is organized in Washington, DC, with satellite marches in cities around the world, to champion the science that upholds the common good.

For the second year, the Cochrane contibuters and supporters around the globe marched for science! Will you march with us in 2019?

Friday, April 20, 2018

New Cochrane-wide peer review policy

Fri, 04/20/2018 - 16:09

On Monday 16th April Cochrane published the first Cochrane-wide peer review policy.  In addition to standardising current practice across all of Cochrane’s 53 Review Groups, the introduction of the new policy aims to improve transparency in communication and decision making, consistent with core Cochrane principles, and taking the opportunity to implement current best practice.

The key highlights of the new policy include:

  • From January 2019 Cochrane will adopt a named peer review policy, whereby authors and peer reviewers know each other’s identities during the peer review process.
  • A decision workflow for deciding when to peer review updated protocols and updated Cochrane Reviews.
  • A minimum number and type of peer reviewer.
  • A minimum standard for acknowledgement of peer reviewer contributions.

As the policy will require some Cochrane Review Groups to change the current practice significantly, the policy will be implemented between now and January 2019, with the aim that each Cochrane Review Group will be compliant with the new policy by January 2019.

If you have any comments of questions about the peer review policy, please contact Bryony Urquhart, Editorial and Methods Department.

David Tovey
Editor in Chief

Thursday, April 26, 2018

Cochrane at the 2018 Medical Library Association (MLA) Meeting

Tue, 04/17/2018 - 17:43

The annual Medical Library Association (MLA) Meeting is a premier event that draws thousands of medical librarians and other health information professionals from around the globe. The meeting is a 4 and 1/2 day interdisciplinary educational experience, with a 3-day commercial exhibition. In 2018, the meeting will take place in Atlanta, USA from 18-23 May.

Our publisher, Wiley, and members of the Cochrane team will be attending. We invite you stop at the Wiley booth (#311), 19-21 May for demonstrations and information about the Cochrane Library. Some live demonstrations include:

  • Cochrane Interactive Learning: learn about introduction modules on how to conduct a systems review of interventions
  • How to search the Cochrane Library
  • Tops tips for using the Cochrane Library
  • Meet the experts: have all your questions answered

The well-attended Cochrane Library sunrise session be run again this year on Sunday 20 May at 7am. Carol Lefebvre, Independent Information Consultant and Co-Convenor, Cochrane Information Retrieval Methods Group will outline how the Cochrane Library continues to be an essential tool for evidence-based medicine, provide you with search tips, and answer your questions.

On Monday 21 May, 10: 35am, members of Cochrane’s Editorial Unit will present on ‘Search Filter to Identify Reports of Randomized Controlled Trials in CINAHL.’

The 2018 MLA meeting will be a great opportunity to meet with Cochrane experts and learn more about the Cochrane Library. We’re looking forward to meeting you at booth 311!

Tuesday, April 17, 2018

List of countries eligible for free one-click access to the Cochrane Library in 2018

Thu, 04/12/2018 - 14:34

We are delighted to confirm that Wiley will offer free one-click access to the Cochrane Library including more than 10,000 full text Cochrane Systematic Reviews and Protocols in over 100 countries with approximately 2.1 billion people. One-click free access is provided by country IP recognition for all the included countries, so no individual login is needed. Users from the eligible countries can simply go to www.cochranelibrary.com to gain full text access to Cochrane Reviews.
 

Effective 1 May 2018, Argentina will graduate out of the free access program. The country list is reviewed by Wiley and Cochrane annually, and is informed by the HINARI Access to Research in Health Programme list http://www.who.int/hinari/en/.
 

To find out if you are eligible to benefit from one-click free access, please visit the Cochrane Library access information page.

Thursday, April 12, 2018

Opportunity for some keen tweeters to come to the Cochrane Colloquium 2018

Tue, 04/10/2018 - 19:33

Announcing a great opportunity for some keen tweeters to come to the Cochrane Colloquium 2018 (with free registration, accommodation and a travel bursary) as part of the #BeyondTheRoom team.

We’re really excited about this. Not ‘excited’ as in “we know we need to appear enthusiastic about this and this is an easy word to reach for” kind of excited, but actually excited!

In Edinburgh this September (Sunday 16th – Tuesday 18th) Cochrane UK is hosting Cochrane’s annual global conference, the Cochrane Colloquium. It will bring together around 1200 people who are interested in producing, sharing and using high quality evidence to inform health decisions.

Through talks, workshops and other activities and presentations, we will be exploring the broad themes of producing evidence, making evidence accessible and advocating for the use of evidence in making choices about health. There will be opportunities to meet new people, share ideas, take part in a variety of activities and maybe start new work together.

This year the theme is #CochraneForAll and, for the first time, it will be a Patients Included event. We are delighted to be involving patients and other healthcare consumers in the planning and delivery of the conference to a greater extent than ever before. We believe there are potential benefits for everyone in doing this, not only through enriching the conversations and ways of working together at the event, but also for improving the quality and relevance of Cochrane evidence and how it is shared and used. 

The event is not all work and no play. You can also look forward to a lively social programme.

Going #BeyondTheRoom

Also new this year is that we’re putting together a team to take the event #BeyondTheRoom. This digital conference service was started in 2016 by André Tomlin from the Mental Elf who saw an opportunity to increase the reach and impact of health events by live tweeting and podcasting from them, to involve people virtually and facilitate a much more democratic conversation (www.beyondtheroom.net). The #BeyondTheRoom team will include André and his colleague Douglas Badenoch, myself and Selena from Cochrane UK, and some new recruits – perhaps it could be you!

André explains:

“Our #BeyondTheRoom service helps health events reach the right audience. All too often, conversations at conferences are dominated by just a few voices. We open up the discussion to everyone who wants to be involved, but also work hard before the event to create a buzz and start to explore some of the key conference themes.”

Do you want to be part of the #BeyondTheRoom team at the Cochrane Colloquium?

We’re looking to add three people to the team. You are welcome to apply if you are a student (of any discipline, with an interest in health evidence), a patient/other healthcare consumer, or a health professional/allied health professional.

This is a brilliant opportunity to be part of an advanced social media activity, increase your visibility, and participate in our conference as a valued team member.

If you’re selected:

You will get free registration for the 3 days of the conference, including lunches and attendance at the Welcome Reception and Gala dinner, four nights accommodation and up to £200 for travel costs (reasonable costs, standard class travel). 

You will be part of the #BeyondTheRoom team:

  • ahead of the event. A lot of work goes into #BeyondTheRoom ahead of the event, including preparing material to share on Twitter at the event. Each member of the team will need to do some of this preparation, which can be done remotely.
  • at the event. All team members will be involved in Tweeting from the key talks and some other sessions. There may be opportunities to be involved in other activities such as podcasting and blogging, according to your skills and preferences.
  • after the event. Write or contribute to a blog about the event and your #BeyondTheRoom experience.
What we are looking for

We are looking for experienced tweeters who can hit the ground running. We’ll be aiming to put together a team with a variety of experience and style! Familiarity with Cochrane and systematic reviews is not essential. Enthusiastic and interested people who are confident using Twitter are what we need!

How to apply

Complete and submit this form, telling us about yourself, why you’d like to do it and what you can bring to it. You are also welcome to get in touch via email if you’d like to find out more: general@cochrane.nhs.uk

Closing date: 4th May

Notification of the outcome by 14th May.

This is a brilliant opportunity. Please spread the word!

You can find us on Twitter @CochraneUK @SarahChapman30 @Mental_Elf #BeyondTheRoom 

Wednesday, April 11, 2018

Cochrane is delighted to announce the official launch of Cochrane Mexico

Mon, 04/09/2018 - 15:25

Cochrane and the Cochrane Iberoamerican Network are delighted to announce the launch of a new Centre in Mexico.

The Mexican Cochrane Centre consists of five Associated Centres located at Culiacán (Sinaloa's Pediatric Hospital), Guadalajara (University of Guadalajara), Mexico City (Mexico's Children Hospital Federico Gómez and Clínica Médica Sur Foundation) and Cuernavaca (National Institute of Public Health).

The Mexican Cochrane Centre will promote evidence-based decision making in health care in Mexico  by supporting and training new Mexican authors of Cochrane Reviews, as well as working with clinicians, professional associations, policy-makers, patients, and the media to encourage the dissemination and use of Cochrane evidence.

The Mexican Cochrane Centre is part of Cochrane, a global independent network of researchers, professionals, patients, carers and people interested in health. Cochrane works with collaborators from more than 130 countries to produce credible, accessible health information that is free from commercial sponsorship and other conflicts of interest.  Cochrane’s work is recognized as representing an international gold standard for high quality, trusted information.

The Mexican Cochrane Centre will be led by the coordinators of the five Associated Centres,  which will offer methodological support, mentoring, and supervision in the country.

The Director of Cochrane Mexico, Giordano Pérez-Gaxiola, says this is a hugely exciting opportunity: “The launch of the Mexican Cochrane Centre is very important, both to Mexico and globally. Producing and increasing the dissemination of the best available information on health care is critical for clinicians and patients everywhere in the world, including Mexico”

Cochrane’s CEO Mark Wilson,  warmly welcomed today’s news, “I am delighted we are announcing the Mexican Cochrane Centre which, by working closely together, will deepen and expand the scope, reach, and impact of Cochrane activities on health and healthcare decision making across Mexico. This is also an important announcement for global health research. The Mexican Cochrane Centre will promote recognition of studies conducted and published in Mexico and this will not only simply increase the access of evidence, but also promote sharing of clinical experiences across the country, and the world.”

For further information, please contact,

Jo Anthony

Senior Media and Communications Manager, Cochrane 

M +44(0) 7582 726 634 E janthony@cochrane.org or pressoffice@cochrane.org

About Cochrane
Cochrane is a global independent network of researchers, professionals, patients, carers and people interested in health.

Cochrane produces reviews which study all of the best available evidence generated through research and make it easier to inform decisions about health. These are called systematic reviews.
Cochrane is a not-for profit organisation with collaborators from more than 120 countries working together to produce credible, accessible health information that is free from commercial sponsorship and other conflicts of interest. Our work is recognised as representing an international gold standard for high quality, trusted information.

Find out more at cochrane.org
Follow us on twitter @cochranecollab

If you are a journalist or member of the press and wish to receive news alerts before their online publication or if you wish to arrange an interview with an author, please contact the Cochrane press office: pressoffice@cochrane.org

Wednesday, April 11, 2018

Stipends deadline for Cochrane Colloquium Edinburgh 2018

Mon, 04/09/2018 - 13:23
Stipend applications closing Friday 27 April 2018

A number of stipends and bursaries are available to help consumers and other attendees based in developing countries to attend Cochrane Colloquium Edinburgh 2018.

The stipends (funding you can apply for, if eligible) are to help cover registration, travel, accommodation, and other expenses associated with attending the 2018 Colloquium.

Cochrane are providing stipends for: 1) Cochrane Consumers; 2) Cochrane contributors living in low-, lower-middle-, (LMIC) and upper-middle-income countries (UMIC); 3) students living in LMIC and UMIC countries.

The deadline for applying is Friday 27 April 2018.

Follow the link to find out whether you are eligible and how to apply: colloquium.cochrane.org/stipends-and-bursaries

Further information: Tuesday, April 10, 2018

Featured Review: Uterotonic agents for preventing postpartum haemorrhage

Thu, 04/05/2018 - 15:59

New evidence on the best drugs to prevent postpartum haemorrhage point away from Oxytocin – the standard drug currently used to treat this condition.

  • Bleeding after birth is the most common reason why mothers die in childbirth worldwide.
  • Includes data from 88,000 women across 140 trials.
  • The review found that ergometrine plus oxytocin, misoprostol plus oxytocin, and carbetocin were more effective drugs for reducing excessive bleeding at childbirth than oxytocin which is the current standard drug used to treat this condition.

Bleeding after birth is the most common reason why mothers die in childbirth worldwide. Although most healthy women can cope well with some bleeding at childbirth, others do not, and this can pose a serious risk to their health and even life. To reduce excessive bleeding at childbirth, the routine administration of a drug to contract the uterus (uterotonic) has become standard practice across the world.

The aim of this research from Cochrane Pregnancy and Childbirth was to identify which drug is most effective in preventing excessive bleeding after childbirth with the least side-effects.

Different drugs given routinely at childbirth have been used for preventing excessive bleeding. They include oxytocin, misoprostol, ergometrine, carbetocin, and combinations of these drugs, each with different effectiveness and side-effects. Side-effects may include: vomiting, high blood pressure and fever. We analysed all the available evidence to compare all of these drugs and calculated a ranking among them, providing robust effectiveness and side-effect profiles for each drug.

This network meta-analysis includes 140 randomised trials with data from 88,947 women.

The authors’ of the review concluded:

Ergometrine plus oxytocin, misoprostol plus oxytocin, and carbetocin were more effective drugs for reducing excessive bleeding at childbirth than oxytocin which is the current standard drug used to treat this condition.

Carbetocin has the least side-effects (less vomiting, high blood pressure and fever) among the top three drug options, but to date studies of carbetocin were small and of poor quality.

There are some ongoing studies that are not yet complete, including two key studies. One is a large study (involving around 30,000 women across 10 different countries) comparing the effectiveness of carbetocin versus oxytocin for preventing PPH among women having a vaginal birth. The other is a UK-based trial (involving more than 6000 women) comparing carbetocin, oxytocin and ergometrine plus oxytocin combination. Both trials are expected to report in 2018 and these results will be incorporated when this review is updated.

University of Birmingham Clinician Scientist Dr Ioannis Gallos, of the Cochrane Pregnancy and Childbirth Group and Review Author, said: "Whilst postpartum haemorrhage is a rare complication, it is the most common reason why mothers die in childbirth worldwide and happens because a woman's womb has not contracted strongly enough after birth or the placenta has been left in the womb and results in excessive bleeding.

"Currently, to reduce excessive bleeding at childbirth, the standard practice across the world is to administer to women during the third stage of labour a drug called oxytocin - a uterotonic which contracts the uterus and stimulates contractions to help push out the placenta.

"However, there are a number of other uterotonics and combinations of these drugs that can be given that may be more effective and result in fewer side effects.

"By analysing data from 140 different clinical trials involving over 88,000 women, we have been able to use evidence to compare all of these drugs and calculate a ranking among them, providing robust effectiveness and side-effect profiles for each drug.

"Our research is important as it has highlighted which drugs may be more effective than oxytocin and we hope that this could impact existing recommendations worldwide."

This Cochrane review is expected to be updated later this year to incorporate the results of some key ongoing studies which will report their findings in coming months, including a large study involving around 30,000 women across 10 different countries comparing the effectiveness of carbetocin versus oxytocin for preventing bleeding in women having a vaginal birth, and a UK-based trial involving more than 6,000 women comparing carbetocin, oxytocin and ergometrine plus oxytocin combination.

Wednesday, April 25, 2018

Cochrane Lung Cancer seeks author of systematic reviews in English language - Besancon, France

Wed, 04/04/2018 - 16:10

The Lung Cancer Group is looking for an author of systematic reviews in English language

You will participate in the writing of the LCG systematic reviews from the registration of the titles until the publication of the reviews.

Missions and activities

Mission 1:  Participation in the systematic reviews of the group

Activities :      

  • Writing  review protocols
  • Bibliographic search
  • Selection of studies to be included in reviews
  • Data extraction
  • Assessment of risk of bias in included studies
  • Writing reviews
  • Regular updates of existing reviews
  • Participation in the peer review of reviews submitted to the group by external authors

Mission 2:  Seeking finance

Activities :

  • Identification of possible sources of funding
  • Writing funding applications

Mission 3:  Literature monitoring in lung cancer

Activities :  

  • Identification of reviews and other sources of information
  • Reading and integration of the latest news in lung cancer
  • Diffusion of the relevant information to the LCG

Skills 

  • English : read, written and spoken, excellent level required 
  • Writing skills
  • Ability to work autonomously
  • Rigorous approach and organisational skills
  • A medical background would be an advantage
  • Knowledge on cancer research, ideally on lung cancer
  • Basic understanding of medical statistics

Please send your application to lungcancergroup@chu-besancon.fr before 15 June 2018

Wednesday, April 4, 2018 Category: Jobs

WHO EURO staff training in collaboration with Cochrane

Tue, 04/03/2018 - 20:00

“In the end, this will improve health around the world,” said Maria Emilia Aragon de Leon, a consultant with the Division of Policy and Governance for Health and Well-being, who attended bothfull-day workshops on systematic reviews and qualitative evidence synthesis. She clarified: “Even though we are not necessarily producing evidence in our program, we are using it. These workshops can help any WHO staff member make better use of the evidence to make informed choices about the policies, plans, strategies and interventions we recommend.”

“At university” she continued, “you normally get an introduction to systematic reviews and methods. These workshops went into much more detail about which tools are available, which steps you need to follow, and they introduced me to the methods for systematic reviews for qualitative studies, which I was not familiar with at all. In general, both workshops helped me better understand how to assess evidence and make sure I use high-quality information only.”



The two workshops on 14 and 16 February 2018 consisted of a combination of presentations, hands-on exercises, interactive sessions, plenary sessions and group discussions. They were organized by the Division of Information, Evidence, Research and Innovation and its Knowledge Management, Evidence and Research for Policy-Making (KER) unit in line with the mandate of the Evidence-informed Policy Network (EVIPNet) Europe in collaboration with Cochrane and with the support of the WHO/Europe Staff Development Team. Both workshops were wellattended by staff and consultants from divisions and units across the European Regional Office.

The benefits of training in Cochrane methodology
Cochrane’s systematic reviews and qualitative evidence syntheses, as well as the methods used to develop them, are widely considered to be the benchmark for high-quality information about the effectiveness of health care and public health nterventions.

Training in Cochrane’s methodology and the conceptual and practical applications for conducting systematic reviews and qualitative evidence synthesis is, therefore, an essential resource for WHO staff: To increase their knowledge and skills on how these reviews are developed and to ensure that their work is based on high-quality, relevant and up-to-date synthesized research evidence.

A focus on the systematic use of quantitative and qualitative evidence
The workshops emphasized the impact of using both quantitative and qualitative reviews on effectiveness as well as implementation and acceptability, and were facilitated experienced Cochrane trainers:

The workshop on systematic reviews on 14 February was co-facilitated by Liliya Ziganshina (Director of Cochrane Russia) together with Livia Puljak (Inaugural Director of Cochrane Croatia and its current Knowledge Translation Coordinator), who both have extensive experience in training a wide range of users in support of fostering research utilization.



The workshop on qualitative evidence synthesis on 16 February was co-facilitated by Ruth Garside (one of the conveners of the Cochrane Qualitative & Implementation Methods Group) who has extensive experience in both qualitative evidence synthesis and implementation research, and Heather Ames (Cochrane Norway), a pioneer in using CERQual, a transparent method for assessing the confidence of evidence from reviews of qualitative research.

A step towards a stronger partnership – and the use of stronger evidence
The workshops cemented the relationship between Cochrane and WHO. Since 2011, WHO has engaged in meaningful collaborations with Cochrane, which envisions a world of improved health where decisions about health and health care are informed by high-quality, relevant and up-to-date synthesized research evidence.

Co-facilitator Liliya Ziganshina from Cochrane Russia said, “With this workshop, WHO Europe has once again proved its strong commitment to trusted evidence and informed decisions, which are at the very heart of its mandate in health-policy guidance to countries for better health. EVIPNet Europe will continue to develop in the framework of the WHO partnership with Cochrane.”

Tuesday, April 3, 2018

Cochrane Eyes and Vision celebrates 21 years of high quality evidence

Sun, 04/01/2018 - 00:16

Cochrane Eyes and Vision is an international network of individuals working to prepare, maintain, and promote access to systematic reviews of interventions to treat or prevent eye diseases or visual impairment. They also do systematic reviews of the accuracy of diagnostic tests for common ocular diseases or conditions.

Cochrane Eyes and Vision registered as a Cochrane group in April 1997. Since that time, they have published 264 protocols of which 187 (71%) have been converted to full reviews:

  • 41 of these reviews have been updated once;
  • 21 have been updated twice;
  • 13 three times; and
  • 7 reviews updated four or more times.

To celebrate their 21st anniversary, members of Cochrane Eyes and Vision gathered  at the Royal College of Ophthalmologists (RCOphth) in London.  Colleagues from Cochrane Eyes and Vision US Satellite  at John’s Hopkins University Baltimore joined them by Skype. They had a lively discussion, in particular focussing on the prioritisation of review topics going forward.

"As we celebrate the 21st anniversary of Cochrane Eyes and Vision, it is an opportunity for us to look back at all our accomplishments and towards the future for our Review Group,” says Richard Wormald and Jenny Evans, co-ordinating editors for Eyes and Vision. “We recently had a lovely celebration of the last 21 years and are looking forward to the future, in particular working with the new Long-term Conditions and Ageing Network and focussing on global priorities for new and updated review."

Thursday, April 5, 2018

Learn how you can contribute to health evidence with Cochrane Crowd

Thu, 03/29/2018 - 15:01

Cochrane Crowd is an online citizen science platform that enables anyone with an interest in health to contribute to health evidence. Our volunteers make it easier for health researchers to find the latest, high-quality evidence on what treatments work and don’t work. This means health practitioners can more easily access current evidence to inform the treatments they provide. Just a few minutes each day makes a huge difference.

This webinar introduces Cochrane Crowd and how you can get involved.

Tuesday 17th April 12.30-1.30pm AEST
Register for free


Can’t make it at this time? We will tweet the webinar recording once it’s available, so follow us at @cochrane_crowd.

crowd.cochrane.org

Support for Project Transform was provided by Cochrane and the National Health and Medical Research Counc12/12/1996il of Australia (APP1114605). The contents of the published material are solely the responsibility of the Administering Institution, a Participating Institution or individual authors and do not reflect the views of the NHMRC.

Thursday, March 29, 2018

Cochrane seeks Executive Assistant to Editor in Chief - London, UK

Wed, 03/28/2018 - 17:38

Specifications: Full Time
Salary: Competitive
Location: London
Application Closing Date: 20th April 2018

This role is an exciting opportunity to use your experience as an Executive Assistant to make a difference in the field of health care research. 

To provide an efficient and responsive administrative, organisational, and logistical service to the Editor in Chief (EiC), Deputy Editor in Chief and Editorial and Methods Department (EMD) leadership team, helping them to manage and prioritise their time and to support the strategic aims and operational activities of the department.

We are looking for a self-motivated and highly organised individual who is able to work effectively and collaboratively with a diverse range of contacts across the world.  The successful candidate will also have:

  • Previous PA/Secretarial experience at a senior level.
  • Excellent typing skills - speed and accuracy essential.
  • Intermediate IT skills, including Word, Excel and PowerPoint.
  • Ability to prioritise and manage own workload amid conflicting demands and busy work periods.
  • Excellent interpersonal skills.
  • Excellent communication skills, both verbal and written.
  • Ability to communicate confidently with people at all levels.
  • Proven ability to work under pressure and to tight deadlines.
  • Ability to exercise discretion and diplomacy in dealing with confidential or sensitive matters.

Cochrane is a global, independent network of health practitioners, researchers, patient advocates and others, responding to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesizing research findings to produce the best available evidence on what can work, what might harm and where more research is needed. Our work is recognised as the international gold standard for high quality, trusted information.

If you would like to apply for this position, please send a CV along with a supporting statement to recruitment@cochrane.org with “Executive Assistant to Editor in Chief” in the subject line.  The supporting statement should indicate why you are applying for the post, and how far you meet the requirements for the post outlined in the job description using specific examples.  List your experience, achievements, knowledge, personal qualities, and skills which you feel are relevant to the post.

Deadline for applications: 20th April 2018 (Midnight)
Interviews to be held on: (TBC)

Wednesday, March 28, 2018 Category: Jobs

Featured Review: Reminiscence Therapy for Dementia

Mon, 03/26/2018 - 20:25

Looking at the discussion of memories and past experiences using tangible prompts such as photographs or music to evoke memories and stimulate conversation.

Reminiscence Therapy (RT) involves the discussion of memories and past experiences with other people using tangible prompts such as photographs or music to evoke memories and stimulate conversation. RT may be offered to groups of people with dementia (in some cases with their family carers also involved) or on a one-to-one basis, often resulting in a life story book.

This updated Cochrane Review of reminiscence therapy for dementia was first published in 1998, and last updated in 2018.

We wanted to find out what effect reminiscence therapy has on people with dementia. In particular, we were interested in effects on quality of life, communication, cognition (the general ability to think and remember), mood, daily activities and relationships. We were also interested in any effects on carers.

In the absence of disease modifying pharmacological treatments for the dementias, psychosocial approaches offer the potential for people with dementia to experience the best possible quality of life. Reminiscence approaches have been used with people with dementia for many years – probably the most popular psychosocial approach in fact. Yet, only in this up-dated review are we seeing sufficient research of reasonable quality to enable evidence-based recommendations about its use and effects.

Not all ‘Reminiscence therapy’ is the same in its effects on people with dementia and carers. We were encouraged to find that the amount and quality of research on RT for dementia has increased considerably since the last version of this review. We concluded that the effects of RT vary, depending on the way it is given and whether it takes place in care homes or the community. However, there is some evidence that RT can improve quality of life, cognition, communication and possibly mood in people with dementia in some circumstances, although all the benefits were small. More research is needed to understand these differences and to find out who is likely to benefit most from what type of RT. Positive benefits were most often seen in care home studies. It is possible reminiscence is especially helpful in maintaining personal identity, which becomes more vulnerable with a move to care home, without the familiar prompts and triggers for personal identity embedded in the person’s own home. Research on digital life story books and reminiscence apps is in its infancy, but is likely to have a major impact on the field in years to come.

Monday, July 9, 2018

Featured Review: Reminiscence Therapy for Dementia

Mon, 03/26/2018 - 20:25

Looking at the discussion of memories and past experiences using tangible prompts such as photographs or music to evoke memories and stimulate conversation.

Reminiscence Therapy (RT) involves the discussion of memories and past experiences with other people using tangible prompts such as photographs or music to evoke memories and stimulate conversation. RT may be offered to groups of people with dementia (in some cases with their family carers also involved) or on a one-to-one basis, often resulting in a life story book.

This updated Cochrane Review of reminiscence therapy for dementia was first published in 1998, and last updated in 2005.

We wanted to find out what effect reminiscence therapy has on people with dementia. In particular, we were interested in effects on quality of life, communication, cognition (the general ability to think and remember), mood, daily activities and relationships. We were also interested in any effects on carers.

In the absence of disease modifying pharmacological treatments for the dementias, psychosocial approaches offer the potential for people with dementia to experience the best possible quality of life. Reminiscence approaches have been used with people with dementia for many years – probably the most popular psychosocial approach in fact. Yet, only in this up-dated review are we seeing sufficient research of reasonable quality to enable evidence-based recommendations about its use and effects.

Not all ‘Reminiscence therapy’ is the same in its effects on people with dementia and carers. We were encouraged to find that the amount and quality of research on RT for dementia has increased considerably since the last version of this review. We concluded that the effects of RT vary, depending on the way it is given and whether it takes place in care homes or the community. However, there is some evidence that RT can improve quality of life, cognition, communication and possibly mood in people with dementia in some circumstances, although all the benefits were small. More research is needed to understand these differences and to find out who is likely to benefit most from what type of RT. Positive benefits were most often seen in care home studies. It is possible reminiscence is especially helpful in maintaining personal identity, which becomes more vulnerable with a move to care home, without the familiar prompts and triggers for personal identity embedded in the person’s own home. Research on digital life story books and reminiscence apps is in its infancy, but is likely to have a major impact on the field in years to come.

Tuesday, April 3, 2018

Cochrane Nursing Care brings the latest evidence to nurses

Tue, 03/20/2018 - 18:35
Cochrane Nursing  Care establishes new publication agreement with British Journal of Community Nursing and extends its agreement with the American Journal of Nursing

The Cochrane Nursing Care Field (CNCF) established a brand new publication agreement with the British Journal of Community Nursing. The journal will feature a ‘Cochrane Corner’ column monthly throughout 2018.

The British Journal of Community Nursing is the UK's leading peer-reviewed journal for district nurses, featuring the most current clinical coverage and research on primary care nursing. The periodical is designed to help nurses manage complex cases more effectively, improve case management skills, and help healthcare professionals gain a greater understanding of best practices with a view to improving hospital procedures.

The CNCF is also pleased to announce the highly ranked American Journal of Nursing (AJN) will be extending its existing publication agreement with the Field and has requested production of a further seven summaries on Cochrane reviews. The new agreement will see the Field’s ‘Cochrane Corner’ column feature in this periodical throughout 2018 and into 2019.

The CNCF is delighted this highly subscribed journal continues to appreciate the value in disseminating relevant Cochrane evidence to the international nursing community. With an impact factor of 1.30, the AJN is one of the highest ranked international publications for nurses and healthcare professionals, providing comprehensive and in-depth information to help nurses stay current in their profession. First established in 1900, the AJN is the oldest nursing journal still in publication. In 2009 the journal was selected as one of the "100 Most Influential Journals in Biology and Medicine in the Last 100 Years" by the Biomedical and Life Sciences Division of the Special Libraries Association. Peer reviewed and evidence-based, the AJN’s articles are written by nurses and healthcare professionals who pursue excellence in practice and aspire to advance in their careers, whatever the setting.

Predominantly a clinical practice journal, the AJN publishes clinical reviews, original research, and provides news and analyses related to technology, drugs, management and professional issues and health care trends, offering solutions to the challenges facing today's practicing nurse.

Publication in the AJN has had a significant impact on the broader dissemination of the Field’s summary evidence, helping to get valuable Cochrane research to a larger number of nurses and related healthcare clinicians internationally.

On the journal’s agreement renewal with the CNCF and the continued publication of Cochrane review summaries, Maureen Shawn Kennedy, MA, RN, FAAN, Editor in Chief of the AJN, writes: “We’ve found running periodic instalments of the CNCF’s ‘Cochrane Corner’ a valuable adjunct to our mission of disseminating evidence-based information to our largely clinically based readers.”

“As the oldest continuing circulated nursing journal in the world, the AJN has a legacy of over 115 years of providing nurses with fact-based information to aid them in their practice and career. Today, with so much information available at the touch of a keyboard, it can be difficult to differentiate between what’s research-based and unbiased from that which is sponsored and unsupported by evidence. It’s vital that nurses have access to accurate information and at the AJN, where accuracy is paramount, we rely on the CNCF’s summaries to help us provide that information. We’ve increased the CNCF’s column from quarterly, to now offering the articles to our readers six times or more a year. It’s been increasingly popular and we’re delighted that more of our readers are discovering it.”

Amy Collins, Managing Editor for the American Journal of Nursing, is also an advocate for the dissemination work performed by the CNCF and adamantly supports the journal’s ongoing collaboration with the Field. On the summaries produced by the CNCF Amy writes: “As the Managing Editor of the AJN, I am pleased that we will be continuing our collaboration with the Cochrane Nursing Care Field. Our Cochrane Corner column, which features streamlined summaries of Cochrane reviews, provides nurses with the trusted research they need to inform practice. This fruitful collaboration, which we have enjoyed for several years, marks our commitment to disseminate evidence-based research to our wide nursing audience.”

Tuesday, March 20, 2018

Pages